Asuragen, Inc.
134 articles with Asuragen, Inc.
-
Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market
12/1/2022
Asuragen, a Bio-Techne brand and Oxford Nanopore Technologies plc, announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.
-
FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Asuragen Launches New Kit to Enable Broader Coverage of Gene Variants Linked to Cystic Fibrosis
11/8/2021
Bio-Techne Corporation announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene.
-
Bio-Techne Completes Acquisition of Asuragen, Inc.
4/6/2021
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.
-
Asuragen to Present at Association for Molecular Pathology (AMP) 2020 Annual Meeting
11/10/2020
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host two corporate workshops and present multiple scientific posters highlighting their new and upcoming products at the 2020 Association for Molecular Pathology (AMP) Annual Meeting & Expo, held virtually from November 16-20.
-
Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry
8/3/2020
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, and Asuragen, a molecular diagnostics company delivering easy-to-use products for complex testing in ge
-
Asuragen Announces CE Mark of AmplideX® SMA Plus Kit
7/7/2020
The assay is intended to aid in the diagnosis of and identification of carriers for spinal muscular atrophy (SMA)
-
Asuragen to Present at 2020 European Society of Human Genetics (ESHG) Virtual Conference
6/2/2020
Corporate satellite presentation and scientific posters highlight new AmplideX® testing kits
-
Asuragen Develops Armored RNA Quant® SARS-CoV-2 Control
3/16/2020
New reference material aims to facilitate and expedite global efforts to detect the novel coronavirus
-
FDA Grants Premarket Clearance of Asuragen’s AmplideX® Fragile X Dx and Carrier Screen Kit
2/24/2020
Feb. 24, 2020 13:00 UTC FDA Grants Premarket Clearance of Asuragen’s AmplideX ® Fragile X Dx and Carrier Screen Kit The first IVD for the diagnosis and screening of fragile X syndrome and other FMR1-related disorders AUSTIN, Texas--( BUSINESS WIRE )-- Asuragen, Inc. , a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, today announced that its AmplideX ® Fragile X Dx and Carrier Screen Kit has been c
-
Asuragen Partners with Wave Life Sciences to Develop Companion Diagnostics for Huntington’s Disease
11/25/2019
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, and Wave Life Sciences, a clinical-stage genetic medicines company developing life-changing treatments for people battling devastating diseases, have entered into an agreement for the development and commercialization of companion diagnostics for Wave’s investigational allele-selective therapeutic programs targeting Huntington’s disease (HD).
-
Asuragen Announces Launch of AmplideX® PCR/CE SMN1/2 Plus Kit
11/6/2019
New clinical research tool provides the most comprehensive analysis of genes associated with spinal muscular atrophy of any commercially available reagent kit
-
Asuragen to Present at 2019 Association for Molecular Pathology (AMP) Annual Meeting
10/30/2019
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host three corporate workshops and present multiple scientific posters highlighting their rapidly expanding product portfolio and industry collaborations at the upcoming 2019 Association for Molecular Pathology (AMP) Annual Meeting & Expo November 7-9 in Baltimore.
-
Asuragen to Present at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
10/8/2019
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will highlight its rapidly growing AmplideX product portfolio and its novel data analysis software applications for challenging repetitive sequences at the upcoming American Society of Human Genetics (ASHG) Annual Meeting in Houston, Texas on October 15-19.
-
Asuragen to Present at 2019 European Society of Human Genetics (ESHG) Conference
6/11/2019
Corporate satellite meeting and numerous scientific posters feature new Asuragen products
-
Asuragen NGS System Streamlines Detection of NSCLC-associated DNA Mutations, Gene Fusions, and RNA Expression Targets in Single Workflow
6/4/2019
The targeted NGS panel enables the detection of 135 RNA and 55 DNA variants associated with non-small cell lung cancer
-
Asuragen to Present at 2019 ACMG Annual Clinical Genetics Meeting
3/26/2019
New products for analysis of genes associated with Huntington’s disease and spinal muscular atrophy to be featured
-
Asuragen Portfolio Expansion Continues with Launch of AmplideX® PCR/CE SMN1/2 Kit
3/19/2019
The kit enables the determination of SMN1 and SMN2 exon 7 copy number in less than four hours
-
Asuragen NGS System for Streamlined Detection of RNA Lung Cancer Variants Demonstrates Superior Performance in Multisite Evaluation
1/29/2019
The QuantideX® NGS RNA Lung Cancer Kit shows high sensitivity, accuracy, and reproducibility in detecting actionable RNA fusions and exon skipping events